A Cell Autonomous Free fatty acid receptor 4 - ChemR23 Signaling Cascade Protects Cardiac Myocytes from Ischemic Injury

Sara J. Puccini,[1] Chastity L. Healy,[1] Brian A. Harsch, PhD,[3] Ahmed R. Ahmed,[1] Gregory C. Shearer, PhD,[3*] and Timothy D. O'Connell, PhD[1,2*]

[1]Department of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, MN

[2]Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, MN

[3]Department of Nutritional Sciences, Pennsylvania State University, University Park, PA

[*]Correspondence to:

Timothy D. O'Connell, PhD
Department of Integrative Biology and Physiology
University of Minnesota School of Medicine
3-141 CCRB
2231 6th Street SE
Minneapolis, MN 55414
Email: tdoconne@umn.edu
Phone: 612-625-6750

-and-

Gregory C. Shearer, PhD
Department of Nutritional Sciences
110 Chandlee Laboratory
University Park, PA 16802
Email: gcs13@psu.edu
Phone: 814-847-3040

Abstract

Acute myocardial infarction (AMI) causes ischemic damage and cardiac remodeling that ultimately progresses into ischemic cardiomyopathy (ICM). Coronary revascularization reduces morbidity and mortality from an MI, however, reperfusion also induces oxidative stress that drives cardiac myocyte (CM) dysfunction and ICM. Oxidative stress in CMs leads to reactive oxygen species (ROS) production and mitochondrial damage. Free fatty acid receptor 4 (Ffar4) is a GPCR for long chain fatty acids (FA) that is expressed in multiple cell types including CMs. We have recently shown that CM-specific overexpression of Ffar4 protects the heart from systolic dysfunction in the context of ischemic injury. Mechanistically, in CMs, Ffar4 increases the levels of 18-hydroxyeicosapentaenoic acid (18-HEPE), an eicosapentaenoic acid (EPA)-derived, cardioprotective oxylipin (oxidatively modified FA). 18-HEPE is the precursor for resolvin E1 (RvE1), a cardioprotective, specialized pro-resolving mediator (SPM) that activates the GPCR ChemR23. We hypothesize Ffar4 in CMs protects the heart from oxidative stress and ischemic injury through activation of a CM-autonomous, Ffar4-ChemR23 cardioprotective signaling pathway. Here, we developed an *in vitro* hypoxia reoxygenation (H/R) model (3 hours of hypoxia, 17 hours of reoxygenation) in adult CMs as a model for ischemic injury. In adult CMs subjected to H/R, TUG-891, an Ffar4 agonist, attenuated ROS generation and TUG-891, 18-HEPE, and RvE1 protected CMs from H/R-induced cell death. More importantly, we found that the ChemR23 antagonist α-NETA prevented TUG-891 cytoprotection in adult CMs subjected to H/R, demonstrating that ChemR23 is required for Ffar4 cardioprotection. In summary, our data demonstrate co-expression of Ffar4 and ChemR23 in the same CM, that Ffar4, 18-HEPE, and RvE1 attenuate H/R-induced CM death, and that ChemR23 is required for Ffar4 cardioprotection in H/R support a CM-autonomous Ffar4-ChemR23 cardioprotective signaling pathway.

Introduction

According to the American Heart Association 9.3 million people, 3.2% of the US population, have had a myocardial infarction (MI) (1). While coronary revascularization has decreased mortality following an acute MI, the incidence of ischemic cardiomyopathy (ICM) and heart failure (HF) post-MI has continued to rise (2). Revascularization post-MI can lead to severe cardiac myocyte (CM) dysfunction largely driven by oxidative stress leading to mitochondrial damage and cell death, provoking a multiphasic inflammatory response to drive ICM (3). Therapeutic management of patients post-MI primarily targets reducing afterload and minimizing the risk of a future MI (4). Currently, there are no FDA-approved therapeutics that specifically target reducing oxidative stress post-MI.

Free fatty acid receptor 4 (Ffar4) is a Gq-coupled G-protein coupled receptor (GPCR) for long chain saturated, monounsaturated, and polyunsaturated fatty acids (SFA, MUFA, and PUFA). Previously, we have demonstrated that loss of Ffar4 worsens cardiac outcomes in multiple experimental models of HF, including pressure overload (5), cardiometabolic disease (6), and ischemia-reperfusion (I/R) injury (7). Specifically, in response to I/R, loss of Ffar4 worsened left ventricular (LV) systolic function, without an effect on infarct size in male and female mice, whereas CM-specific overexpression of Ffar4 attenuated LV systolic dysfunction post-I/R (7). Generally, we have found that the loss of Ffar4 impairs cardiac function without an effect on fibrosis.

In CMs, we have demonstrated that Ffar4 signaling through cytoplasmic phospholipase A2α (cPLA2α) induces the production of the eicosapentaenoic acid (EPA, an ω3-PUFA)-derived oxylipin, 18-hydoxyeicosapentaenoic acid (5). Further, loss of Ffar4 was associated with reductions in 18-HEPE levels in the heart and HDL and correlated with worsened outcomes in pathologic mouse models of HF (5, 6). Interestingly, a prior study found that 18-HEPE attenuated pathologic remodeling in pressure overload (8). 18-HEPE is the precursor for resolvin E1 (RvE1), a

cardioprotective, specialized pro-resolving mediator (SPM) that activates the GPCR ChemR23. Prior studies also indicate that RvE1 attenuates cardiac ischemic injury *ex vivo* (9) and *in vivo* (10, 11). Together, these data suggest that Ffar4-mediated production of EPA-derived oxylipins is cardioprotective.

Here, we propose a CM-autonomous Ffar4-ChemR23 cardioprotective signaling pathway that protects CMs from oxidative stress. Specifically, we hypothesize that Ffar4 induces the production of 18-HEPE, which is converted to RvE1 to activate ChemR23, activation of which protects CMs from oxidative stress as illustrated in **Figure 1**. Briefly, our results indicate that Ffar4 and ChemR23 are co-expressed in the same CM, a prerequisite for our model. Using a model of hypoxia-reoxygenation (H/R) to model I/R *in vitro*, we found that activation of Ffar4 attenuated H/R-induced oxidative stress and CM death. Similar results were observed with 18-HEPE and RvE1. Finally, we found that the ChemR23 antagonist, α-NETA, ablated Ffar4 cardioprotection in H/R, indicating ChemR23 is required for Ffar4 cardioprotection. In summary, we have identified a novel CM-autonomous Ffar4-ChemR23 cardioprotective signaling pathway that attenuates oxidative stress.

Methods

Isolation and culture of adult cardiac myocytes: We previously published a comprehensive step-by-step procedure for the isolation and culture of adult mouse cardiac myocytes that was used in this study (12).

Single CM Real Time Quantitative PCR (RT-qPCR): Adapting a previously described protocol (13), freshly isolated adult CMs in standard perfusion buffer were individually pipetted into an single PCR tube in ~5 μl volume using a Stripper Pipette (MXL3-STR) equipped with a 100 µm tip (MXL3-100) from Cooper surgical (Brand: ORIGIO) and flash-frozen in liquid nitrogen.

Reverse Transcription: cDNA libraries were synthesized from single CMs in a two-step process in a final total volume of 20 μL. Step 1, the following reagents were added to each tube containing 1 cell in ~5 μL: 2 μL M-MuLV Reverse Transcriptase Reaction Buffer (New England Biolabs (NEB), Ipswich, MA, Cat. #M0253), 5 μM Oligo(dt) Primer (ThermoFisher, Waltham, MA, Cat. #18418012), 60 μM Random Hexamer Primer (NEB, Cat. #S1330S), and Nuclease Free Water up to a final volume of 16 μL. The tubes were heated to 65°C for 10 minutes then placed on ice. Step 2, the following reagents were added to each reaction: 1 mM dNTP (NEB, Cat. #N0447), 20 U RNase Inhibitor (NEB, Cat. #M0353), 35 U Reverse Transcriptase (NEB, Cat. # M0253), and nuclease free water up to final volume of 20 μL. In a thermocycler, the reactions were heated to 25°C for 10 minutes, 55°C for 30 minutes, and then 85°C for 5 minutes, and the reactions were subsequently cooled on ice. cDNA preparations were then purified utilizing a Qiagen QIAquick PCR purification kit (Qiagen, Germantown, MD) with an elution volume of 50 μL.

Pre-Amplification: Primers for specific genes of interest were pooled based on annealing temperatures and level of expression for “primer pool” pre-amplifications.

Pool 1: RPL32 and cTNT, Pool 2: Ffar4, and Pool 3: ChemR23. Primer pool mixes were prepared at a concentration of 1 μM. For each pre-amplification reaction, we combined 2.25 μL of the 1 μM primer pool mix, 10 μL 2x iTaq Universal SYBR Green (BioRad, Hercules, CA, Cat. #1725120), 5 μL of cDNA, and 2.75 μL nuclease free water for a final volume of 20 μL. Reactions were amplified using the following cycling parameters: 1X: 95°C for 3 minutes; 19X: 95°C for 20 seconds, annealing temp for specific primers for 4 minutes, 72°C for 20 seconds; and 1X: 72°C for 5 minutes, and following the reaction, amplified cDNA was diluted 1:2 with nuclease free water.

RT-qPCR: RT-qPCR was performed using a BioRad CFX96 Real-Time System thermocycler. For each reaction we combined 1.5 μL of cDNA, 100nM primers, 5 μL 2x iTaq Universal SYBR Green (BioRad, Cat. #1725120) and nuclease free water up to 10 μL. Reactions were amplified using the following cycling parameters: 1X: 95°C for 30 seconds and 39X: 95°C for 5 seconds, annealing temp for 30 seconds + data capture. All qPCR results are verified with DNA gel electrophoresis.

Table 1: RT-qPCR primer sequences

Gene	Annealing Temp (°C)	Forward Primer	Reverse Primer
RPL32	57	GGTGGCTGCCATCTGTTTTAC	GATCTGGCCCTTGAACCTTCT
cTNT	57	CAGAGGAGGCCAACGTAGAAG	CTCCATCGGGGATCTTGGGT
Ffar4	65	CGGCGGGGACCAGGAAAT	GTCTTGTTGGGACACTCGGA
ChemR23	59	CTGTTCAACATCTTTTTGCCGAT	GAGCAGGTCATGTAGGCCA

Hypoxia/Reoxygenation (H/R): Adult CMs were isolated and cultured in 35 mm tissue culture dishes as described above and subjected to H/R using an adaptation of a previously described protocol (14). Briefly, prior to hypoxia, CMs are pretreated with

either TUG-891 (10 μM, overnight, Cayman Chemicals, Ann Arbor, MI, Cat. #17035), 18-HEPE (100 nM, 2 hours, Cayman Chemicals, Cat. #32840), resolvin E1 (100 nM, 2 hours, Cayman Chemicals, Cat. #10007848), α-NETA (100 nM, overnight, Cayman Chemicals, Cat. #15125), or vehicle. To prepare hypoxic culture medium prior to adding to CMs, culture medium was bubbled in a 50ml conical for 30 minutes with a nitrogen gas mixture containing 94% N_2, 5% CO_2, and 1% oxygen. To induce hypoxia, the cell culture medium was changed to hypoxic medium with either the treatment of interest or vehicle. CMs were then placed inside a hypoxia chamber (STEM CELL Technologies, Vancouver, BC, Canada, Cat. #27310) filled with the nitrogen gas mixture for 3 hours. After 3 hours, reoxygenation was initiated by removing CMs from the hypoxia chamber and changing the culture medium back to normoxic medium containing the treatment of interest or vehicle for up to 17 hours. CM death was measured at 17 hours, whereas CellROX staining to measure ROS generation was measured after 4 hours of reoxygenation.

Quantification of CM death induced by H/R: Following 17 hours of reoxygenation, cell death was quantified by assessing cell morphology (rod shape: viable; round: dead) for duplicate culture dishes for each condition, quantifying at least 100 myocytes from 5 randomly selected fields in each culture dish as we have previously described (15-18).

Quantification of Reactive Oxygen Species (ROS) induced by HR: Following 4 hours of reoxygenation, CM ROS was quantified using CellROX Deep Red (ThermoFisher, Cat. #C10422), a fluorescent dye used to detect ROS generation. Briefly, CellROX (5 μM) was added to the culture medium for 30 minutes at 37°C. After 30 minutes, CMs were fixed in a two-step process, 1) 10 minutes with 2% paraformaldehyde, and 2) 10 minutes with 4% paraformaldehyde. After fixation CMs were stained with DAPI (4′,6-diamidino-2-phenylindole) and mounted on microscope

slides. To detect CellROX fluorescence, CMs were excited at 649 nM and images were captured using a 667 nM filter with a 10X objective on a Keyence BZ-X810 Fluorescence Microscope (Keyence, Osaka, Japan). Mean fluorescent intensity (MFI) for individual CMs was measured using ImageJ (19), and background intensity was subtracted.

Oxylipin Production induced by H/R

CM preparation: Following 17 hours of reoxygenation, cell culture medium was removed, CMs were rinsed with warm PBS, and placed in a 1:1 mixture of PBS:Methanol. CM were scraped and collected into the PBS:Methanol solution and flash-frozen in liquid nitrogen.

Sample Extraction: Samples were thawed on ice and extracted using a previously well-defined protocol (5). CMs were spiked with BHT/EDTA (0.2 mg/mL), a surrogate containing deuterated oxylipins (20 uL of 1000 nM concentration), and subjected to liquid-liquid extraction to isolate lipid content. Samples were split in two, a non-hydrolyzed portion for free oxylipin measurement, and a hydrolyzed portion for total oxylipin measurement using 0.1 M methanolic sodium hydroxide and further purification by solid phase extraction using a Chromabond HLB sorbent column. Oxylipins were eluted with 0.5 mL of methanol with 0.1% acetic acid and 1 mL of ethyl acetate, dried under nitrogen stream, and reconstituted with 100 nM 1-cyclohexyluriedo-3-dodecanoic acid (CUDA) in methanol acetonitrile (1:1).

LCMS Analysis: Samples were analyzed by liquid chromatography using a Waters Acquity UPLC coupled to Waters Xevo triple quadrupole mass spectrometer equipped with electrospray ionization source (Waters, Milford, MA). A volume of 5 μL was injected and separation was performed using a CORTECS UPLC C18 2.1 x 100 mm with 1.6 μM particle size column for oxylipin analysis. Flow rate was set at 0.5 mL/min and consisted

of a gradient run using water with 0.1% acetic acid (Solvent A) and acetonitrile isopropanol, 90:10 (Solvent B) for 15 minutes (0-12 min from 25% B to 95% B, 12-12.5 min 95% B, 12.5-15 min 25% B). Electrospray ionization operated in negative ion mode with capillary set at 2.7 kV, desolvation temperature set at 600°C, and source temperature set to 150°C. Optimization of oxylipin MRM transitions were identified by direct injection of pure standards onto the mass spectrometer and using cone voltage and collision energy ramps to optimize detection and most prevalent daughter fragments. Calibration curves were generated prior to each run using standards for each oxylipin. Peak detection and integrations were achieved through Target Lynx (Waters, Milford, MA) and each peak inspected for accuracy and corrected when needed.

Statistics: All data are presented as mean ± SEM, and a Shapiro-Wilk test was used to test for a normal distribution. Comparisons of multiple groups were performed using a two-way ANOVA with repeated measures and a Tukey's post-test with Prism 10.0 (GraphPad Prism, San Diego, CA). $P<0.05$ was considered significant. Results of post-test comparisons are only shown when the primary interaction was significant.

Results

Ffar4 and ChemR23 are co-expressed in adult CMs.

Here, we have advanced a hypothetical model for a CM-autonomous signaling mechanism in which Ffar4 activation leads to the production of the ligand for another GPCR, ChemR23 to protect CMs from oxidative stress (Figure 1). As a requisite for this hypothesis to be correct, both Ffar4 and ChemR23 must be co-expressed in CMs. To evaluate this assertion, we created cDNA libraries from individual adult CMs and used RT-qPCR to measure receptor expression. In support of our hypothesis, we detected Ffar4 and ChemR23 co-expression in all the CMs tested (Figure 2).

Ffar4 (TUG-891) attenuates cell death and ROS generation induced by hypoxia-reoxygenation (H/R) in adult CMs. We recently demonstrated that CM-specific overexpression of Ffar4 attenuated systolic dysfunction post-I/R (7). To define the mechanistic basis for the purported Ffar4 cardioprotective effects post-I/R, we developed an *in vitro* model of H/R in which adult CMs were subjected to 3 hours of hypoxia followed by 17 hours of reoxygenation to simulate I/R *in vitro*. In adult CMs subjected to this 3/17-H/R protocol, H/R increased CM death by 48.67% ± 7.82% (percent increase in cell death ± SEM) (Figure 3A and 3B, green symbols). Interestingly, the Ffar4-specific agonist, TUG-891 (10 μM), attenuated H/R-induced CM death by 126.09% ± 16.48% (Figure 3A and 3B, closed symbols). Additionally, we measured reactive oxygen species (ROS) generation as a marker of oxidative stress after 3 hours of hypoxia and 4 hours of reoxygenation. The 4 hour reoxygenation timepoint was chosen as a time at which CMs were actively dying. The 3/4-H/R protocol increased CM ROS levels by 85.99% ± 23.27% (Figure 3C and 3D, green symbols), whereas TUG-891 attenuated H/R-induced ROS generation by 117.50% ± 23.00% (Fig. 3C and 3D, closed symbol).

Previously, we observed that activation of Ffar4 in adult CMs induced the production of 18-HEPE (5), whereas loss of Ffar4 reduced 18-HEPE levels in the heart and HDL, which correlated with worsened outcomes in HF (5, 6). Here, we measured Ffar4-mediated production of 18-HEPE in our 3/17-H/R model. In adult CMs, H/R had no effect on 18-HEPE levels, but we confirmed our previous result that TUG-891 (10 μM) increased 18-HEPE levels in adult CMs, regardless of H/R (Figure 3E). Interestingly, the 3/17-H/R model increased 9-HETE levels, but 9-HETE levels were not affected by TUG-891 (Figure 3F). 9-HETE is produced solely through oxidative stress, indicating the effects of TUG-891 on 18-HEPE were specific, not simply a result of oxidative stress. Finally, TUG-891 showed a trend to decrease the levels of the pro-inflammatory oxylipin 12-HETE regardless of H/R (Figure 3G). This correlates with our previous results indicating that loss of Ffar4 was associated with increased 12-HETE levels in heart and HDL *in vivo* (5, 6), and suggests that Ffar4 attenuates 12-HETE production.

Figure 4. 18-HEPE and RvE1 attenuate cell death induced by hypoxia-reoxygenation in adult CMs. To test our hypothesis that Ffar4 cardioprotection is due to an Ffar4-18-HEPE-RvE1-ChemR23 signaling pathway, adult CMs were subjected to the 3/17-H/R protocol and treated with 18-HEPE (100 nM, Figure 4A and 4B) or RvE1 (100 nM, Figure 4C and 4D). Importantly, both 18-HEPE and RvE1 attenuated H/R-induced CM death by 99.00% ± 11.07% (Figure 4A and 4B, closed symbols) and 105.31% ± 7.46% (Figure 4C and 4D, closed symbols) respectively. For both 18-HEPE and RvE1, the magnitude of protection was comparable to TUG-891.

Figure 5. ChemR23 is required for Ffar4 (TUG-891) attenuation of cell death induced by hypoxia-reoxygenation in adult CMs. To determine if ChemR23 is required for Ffar4 cardioprotection, adult CMs were subjected to the 3/17-H/R protocol

and treated with or without TUG-891 (10 μM) and with or without the ChemR23 antagonist α-NETA (100 nM). TUG-891 attenuated H/R-induced CM death (Figure 5A and 5B, green vs maroon symbols), whereas α-NETA ablated TUG-891 cardioprotection by 133.72% ± 14.44% (Figure 5A and 5B, maroon vs blue/maroon symbols). In short, this result indicates that ChemR23 is required for Ffar4 cardioprotection in adult CMs.

Discussion

We have proposed the novel hypothesis that a CM intrinsic Ffar4-18-HEPE/RvE1-ChemR23 signaling axis protects CMs from oxidative stress to attenuate ICM as depicted in **Fig. 1.** Briefly, we show that Ffar4 and ChemR23 are co-expressed in CMs (Fig 2), supporting our proposed cell autonomous signaling pathway. Further, we found that Ffar4 attenuated cell death (Figure 3A and 3B) and oxidative stress (Figure 3C and 3D) in an *in vitro* model of H/R, while similar results were observed with 18-HEPE (Fig 4A and 4B), and RvE1 (Fig 4C and 4D). Lastly, we found that inhibition of ChemR23 prevented TUG-891 induced cardioprotection in H/R (Fig 5). In total, these data support our hypothesis that Ffar4 signaling is cardioprotective via an 18-HEPE/Rve1-ChemR23 signaling axis.

Clinically, increased oxidative stress in CMs following coronary revascularization post-MI drives ICM (20). In CMs, reperfusion and the associated rapid reintroduction of oxygen and nutrients causes oxidative stress, ROS generation, mitochondrial damage, and CM death (3, 20). Recently, in mice with systemic deletion of Ffar4 (Ffar4KO mice), we found that I/R induced a similar and significant decrease in LV systolic function in both male and female WT and Ffar4KO mice after three days, but from that point, systolic function (ejection fraction) recovered to baseline values in WT mice but continued to decrease and remained suppressed in Ffar4KO mice at four weeks (7). Transcriptome analysis indicated failure to induce gene programs associated with mitochondrial metabolism/function in the infarcted myocardium from Ffar4KO mice relative to the infarcted myocardium from wild-type mice or non-infarcted myocardium from Ffar4KO mice (7). In agreement with these findings, we showed here that Ffar4 attenuates H/R-induced oxidative stress and cell death in adult CMs *in vitro* (Figure 3). CMs have a high energy demand and a high mitochondrial mass. Therefore, damaged mitochondria and increased ROS production might trigger CM death (21, 22). Improvements in mitochondrial function might explain the reduction in H/R-induced CM

death observed here. Others have also observed that Ffar4 attenuates oxidative stress. In adipocytes, TUG-891 stimulated fat oxidation, mitochondrial respiration, and mitochondrial fission in brown adipose tissue (23). Further, activation of Ffar4 with docosahexaenoic acid (DHA, an ω-3 PUFA) improved mitophagy and protected hepatocytes from oxidative stress (24). Lastly, in the heart post-MI, Ffar4 protects the heart from oxidative stress induced arrythmias (25).

We have clearly demonstrated, here and in prior published work, that Ffar4 activation activates cPLA2α and subsequent 18-HEPE production (Fig 3E) (5, 6). Suzumara *et al*. published that 18-HEPE protects cells from oxidative stress and cell death in a model of diabetic retinopathy (26). Here, we show that 18-HEPE treatment protects CMs from H/R induced cell death (Fig 4A and 4B). 18-HEPE is the precursor to the specialized pro-resolving mediator (SPM), RvE1. SPMs are derived from ω3-PUFAs and resolve inflammation (27), and prior studies in the heart indicate that RvE1 attenuates ischemic injury *ex vivo* (9) and *in vivo* (10). Zhang *et al*. has shown that RvE1 protects the heart from doxorubicin induced myocardial apoptosis and oxidative stress (28). Here, we show that treating CMs with RvE1 protects against H/R-induced cell death (Fig 4C and 4D). RvE1 is an endogenous ligand for the GPCR ChemR23, ChemR23 has been best characterized in the context of inflammation. Few studies have focused on the role of ChemR23 in the heart. One study investigating ChemR23 in the context of diabetes driven cognitive decline showed that ChemR23 activation by either of its endogenous ligands (RvE1 or Chemerin) protected mice from oxidative stress and inhibited NLRP3 inflammasome activation via activation of antioxidant pathways (29). Here, we demonstrated that Ffar4 cardioprotective signaling required ChemR23. In CMs treated with or without TUG-891 and with or without an inhibitor of ChemR23 (α-NETA), we found TUG-891 induced cardioprotection in H/R was abolished when ChemR23 was inhibited (Fig 5). This data supports our hypothesis that this Ffar4-18-HEPE/RvE1-ChemR23 signaling axis is cardioprotective.

Here, we have described a novel, CM-autonomous Ffar4-ChemR23 signaling pathway that protects CMs from oxidative stress, which we hypothesize will protect the heart from ICM post-MI. Ultimately, targeting Ffar4 with synthetic agonists or endogenous fatty acid ligands, for example icosapent ethyl (Vascepa) might be a novel therapeutic strategy to attenuate ICM post-MI.

Acknowledgements

Disclosures:

None

Funding Sources

This work was supported by grants from the National Institutes of Health, National Heart Lung Blood Institute HLR01152215 (TDO and GCS)

Author Contributions:

Conceptualization: SJP, GCS, TDO

Methodology: SJP, CLH, ARA, BAH, GCS, TDO

Formal analysis: SJP, BAH, TDO

Investigation: SJP, CLH, BAG, ARA, GCS, TDO

Writing-Original Draft: SJP, TDO

Writing-Review & Editing: SJP, CLH, BAH, GCS, TDO

Visualization: SJP, TDO

Supervision: GCS, TDO

Funding Acquisition: GCS, TDO

References

1. Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. *Circulation.* 2024;149(8):e347-e913.
2. Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi S, AlKatheeri R, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. *Cureus.* 2020;12(7):e9349.
3. Sanchez-Hernandez CD, Torres-Alarcon LA, Gonzalez-Cortes A, and Peon AN. Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive Approaches. *Mediators Inflamm.* 2020;2020:8405370.
4. Panahi M, Vadgama N, Kuganesan M, Ng FS, and Sattler S. Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications. *J Clin Med.* 2018;7(11).
5. Murphy KA, Harsch BA, Healy CL, Joshi SS, Huang S, Walker RE, et al. Free fatty acid receptor 4 responds to endogenous fatty acids to protect the heart from pressure overload. *Cardiovasc Res.* 2022;118(4):1061-73.
6. Zhang N, Harsch B, Zhang MJ, Gyberg DJ, Stevens JA, Wagner BM, et al. FFAR4 regulates cardiac oxylipin balance to promote inflammation resolution in HFpEF secondary to metabolic syndrome. *J Lipid Res.* 2023;64(6):100374.
7. Zhang MJ, Karachenets S, Gyberg DJ, Puccini S, Healy CL, Wu SC, et al. Free fatty acid receptor 4 in cardiac myocytes ameliorates ischemic cardiomyopathy. *bioRxiv.* 2024.
8. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J Exp Med.* 2005;201(5):713-22.
9. Keyes KT, Ye Y, Lin Y, Zhang C, Perez-Polo JR, Gjorstrup P, and Birnbaum Y. Resolvin E1 protects the rat heart against reperfusion injury. *Am J Physiol Heart Circ Physiol.* 2010;299(1):H153-64.
10. Zhang J, Wang M, Ye J, Liu J, Xu Y, Wang Z, et al. The Anti-inflammatory Mediator Resolvin E1 Protects Mice Against Lipopolysaccharide-Induced Heart Injury. *Front Pharmacol.* 2020;11:203.
11. Liu G, Liu Q, Shen Y, Kong D, Gong Y, Tao B, et al. Early treatment with Resolvin E1 facilitates myocardial recovery from ischaemia in mice. *Br J Pharmacol.* 2018;175(8):1205-16.
12. O'Connell TD, Rodrigo MC, and Simpson PC. Isolation and culture of adult mouse cardiac myocytes. *Methods Mol Biol.* 2007;357:271-96.
13. Myagmar BE, Flynn JM, Cowley PM, Swigart PM, Montgomery MD, Thai K, et al. Adrenergic Receptors in Individual Ventricular Myocytes: The Beta-1 and Alpha-1B Are in All Cells, the Alpha-1A Is in a Subpopulation, and the Beta-2 and Beta-3 Are Mostly Absent. *Abstract: In the heart, the relative proportions of the 2 forms of the motor.* 2017;120(7):1103-15.
14. Portal L, Martin V, Assaly R, d'Anglemont de Tassigny A, Michineau S, Berdeaux A, et al. A model of hypoxia-reoxygenation on isolated adult mouse cardiomyocytes:

characterization, comparison with ischemia-reperfusion, and application to the cardioprotective effect of regular treadmill exercise. *J Cardiovasc Pharmacol Ther.* 2013;18(4):367-75.
15. O'Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turnbull L, et al. Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. *J Clin Invest.* 2006;116(4):1005-15.
16. Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, and O'Connell TD. An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. *Circulation.* 2007;115(6):763-72.
17. Dahl EF, Wu SC, Healy CL, Perry J, and O'Connell TD. ERK mediated survival signaling is dependent on the Gq-G-protein coupled receptor type and subcellular localization in adult cardiac myocytes. *J Mol Cell Cardiol.* 2018.
18. Huang Y, Wright CD, Kobayashi S, Healy CL, Elgethun M, Cypher A, et al. GATA4 is a survival factor in adult cardiac myocytes but is not required for {alpha}1A-adrenergic receptor survival signaling. *Am J Physiol.* 2008;295(2):H699-707.
19. Schroeder AB, Dobson ETA, Rueden CT, Tomancak P, Jug F, and Eliceiri KW. The ImageJ ecosystem: Open-source software for image visualization, processing, and analysis. *Protein Sci.* 2021;30(1):234-49.
20. Lotz C, Herrmann J, Notz Q, Meybohm P, and Kehl F. Mitochondria and Pharmacologic Cardiac Conditioning-At the Heart of Ischemic Injury. *Int J Mol Sci.* 2021;22(6).
21. Shen S, He F, Cheng C, Xu B, and Sheng J. Uric acid aggravates myocardial ischemia-reperfusion injury via ROS/NLRP3 pyroptosis pathway. *Biomed Pharmacother.* 2021;133:110990.
22. Chen Y, Guo X, Zeng Y, Mo X, Hong S, He H, et al. Oxidative stress induces mitochondrial iron overload and ferroptotic cell death. *Sci Rep.* 2023;13(1):15515.
23. Schilperoort M, van Dam AD, Hoeke G, Shabalina IG, Okolo A, Hanyaloglu AC, et al. The GPR120 agonist TUG-891 promotes metabolic health by stimulating mitochondrial respiration in brown fat. *EMBO Mol Med.* 2018;10(3).
24. Chen J, Wang D, Zong Y, and Yang X. DHA Protects Hepatocytes from Oxidative Injury through GPR120/ERK-Mediated Mitophagy. *Int J Mol Sci.* 2021;22(11).
25. Chen WT, Chen SY, Wu DW, Lee CC, and Lee TM. Effect of icosapent ethyl on susceptibility to ventricular arrhythmias in postinfarcted rat hearts: Role of GPR120-mediated connexin43 phosphorylation. *J Cell Mol Med.* 2020;24(16):9267-79.
26. Suzumura A, Kaneko H, Funahashi Y, Takayama K, Nagaya M, Ito S, et al. n-3 Fatty Acid and Its Metabolite 18-HEPE Ameliorate Retinal Neuronal Cell Dysfunction by Enhancing Muller BDNF in Diabetic Retinopathy. *Diabetes.* 2020;69(4):724-35.
27. Serhan CN, and Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. *J Clin Invest.* 2018;128(7):2657-69.
28. Zhang J, Wang M, Ding W, Zhao M, Ye J, Xu Y, et al. Resolvin E1 protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress, autophagy and apoptosis by targeting AKT/mTOR signaling. *Biochem Pharmacol.* 2020;180:114188.
29. Zhang J, Liu L, Zhang Y, Yuan Y, Miao Z, Lu K, et al. ChemR23 signaling ameliorates cognitive impairments in diabetic mice via dampening oxidative stress and NLRP3 inflammasome activation. *Redox Biol.* 2022;58:102554.

Figure 1.



Fig. 1: A cardiac myocyte (CM) autonomous Ffar4-18-HEPE-RvE1-ChemR23 signaling pathway attenuates ischemic injury. We propose that in adult CMs, activation of Ffar4 induces production of the eicosapentaenoic acid (EPA)-derived, cardioprotective oxylipin 18-hydroxyeicosapentaenoic acid (18-HEPE). Subsequently, 18-HEPE is further oxidatively modified to produce the specialized pro-resolving mediator (SPM) resolvin E1 (RvE1). RvE1 is an endogenous agonist for ChemR23, and activation of ChemR23 attenuates oxidative stress to prevent ischemic injury in adult CMs.

Figure 2.



Figure 2. Ffar4 and ChemR23 are co-expressed in adult CMs. Adult cardiac myocytes were isolated from the hearts of WT mice. A cDNA library was generated for each individual CM followed by a pre-amplification procedure as described. Ffar4, ChemR23, cardiac troponin T (cTnT, a CM control), and RPL32 (a library control) were amplified in separate reactions by qRT-PCR using primers and reaction conditions as described. To validate the PCR procedure, reaction products were separated on an agarose gel, and all reactions demonstrate specific amplicons at the predict molecular weight. Lanes 1-4: 4 individual CMs; Lane 5 (WT): whole heart tissue from a WT mouse; Lane 6 (KO): whole heart tissue from an Ffar4KO mouse; Lane 7 (NTC): a non-template control.

Figure 3.


A.
Vehicle
TUG-891 (10 μM)
Normoxia
Hypoxia
23/7
21/9
21/13
22/9
B.
P<0.0001
P<0.0001
% Cell Death
Hypoxia
TUG-891
C.
Vehicle
TUG-891 (10 μM)
Normoxia
Hypoxia
D.
P=0.0022
P=0.0016
P=0.0009
Normalized CellROX Fluorescence
Hypoxia
TUG-891
E.
P<0.0001
P<0.0001
18-HEPE (nM)
Hypoxia
TUG-891
F.
P<0.0047
9-HETE (nM)
Hypoxia
TUG-891
G.
12-HETE (nM)
Hypoxia
TUG-891

Figure 3. Ffar4 (TUG-891) attenuates cell death and ROS generation induced by hypoxia-reoxygenation in adult CMs. Adult cardiac myocytes were isolated and cultured from the hearts of WT mice, treated overnight with TUG-891 (10 μM) and then subjected to 3 hr of hypoxia followed by 17 hr of reoxygenation. (**A-B**). Cell death was assessed by morphology (rod shape: live; round: dead; (A) CM morphology; (B) quantitation) and (**C-D**) ROS was measured by CellROX fluorescence ((C) CM fluorescence; (D) quantitation). (**E-F**) Quantification of (E) 18-HEPE levels (F) 9-HETE, n=3 (marker of oxidative stress). Data in **B** (n=7), **D** (n=3), **E** (n=3), **F** (n=3), and **G** (n=3) are presented as mean ± SEM and data were analyzed by two-way ANOVA with a Tukey's multiple comparison post-test to detect differences between groups. For determination of a primary interaction, $P<0.05$ was considered significant, and significance between groups ($P<0.05$) identified by the Tukey's post-test are indicated in the figures.

Figure 4.



Figure 4. 18-HEPE and RvE1 attenuate cell death induced by hypoxia-reoxygenation in adult CMs. Adult cardiac myocytes were isolated and cultured from the hearts of WT mice, treated with (**A-B**) 18-HEPE (100 nM) or (**C-D**) RvE1 (100 nM) for 2 hours and then subjected to 3 hr of hypoxia followed by 17 hr of reoxygenation. (**A, C**) Cell death was assessed by morphology (rod shape: live; round: dead) and (**B, D**) quantified. Data in **B** (n=4) and **D** (n=4) are presented as mean ± SEM and data were analyzed by two-way ANOVA with a Tukey's multiple comparison post-test to detect differences between groups. For determination of a primary interaction, $P<0.05$ was considered significant, and significance between groups ($P<0.05$) identified by the Tukey's post-test are indicated in the figures.

Figure 5.



Figure 5. ChemR23 is required for Ffar4 (TUG-891) attenuation of cell death induced by hypoxia-reoxygenation in adult CMs. Adult cardiac myocytes were isolated and cultured from the hearts of WT mice, treated with TUG-891 (10 μM), αNETA (100 nM) or the combination of TUG-891 and αNETA overnight and then subjected to 3 hr of hypoxia followed by 17 hr of reoxygenation. (**A**) Cell death was assessed by morphology (rod shape: live; round: dead) and (**B**) quantified. Data in **B** (n=3) are presented as mean ± SEM and data were analyzed by two-way ANOVA with a Tukey's multiple comparison post-test to detect differences between groups. For determination of a primary interaction, $P<0.05$ was considered significant, and significance between groups ($P<0.05$) identified by the Tukey's post-test are indicated in the figures.